Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis.
Cyclooxygenase-2 (COX-2) enzyme plays an important role in cancer development. COX-2 inhibition by non-steroidal anti-inflammatory drugs is a useful approach for cancer prevention, but its usage has been associated with side effects. n-3 polyunsaturated fatty acids also exhibit a chemopreventive effect mediated by COX-2 inhibition. Therefore, the present study was designed to evaluate the effect of combined dosage of celecoxib and fish oil in experimental mammary carcinogenesis. Female Wistar rats were distributed as control, 7,12-dimethyl benz(α)anthracene (DMBA) treated, celecoxib + fish oil (20 mg/kg b.w. + 0.5 ml), celecoxib + fish oil (30 mg/kg b.w. + 0.25 ml), and their corresponding controls treated with fish oil or celecoxib only. The treatment was given for 7 days, and on the 8th day animals of all the groups except the control group received DMBA orally and sacrificed after 90 days. The histopathology, DNA fragmentation, total sialic acid (TSA), lipid-associated sialic acid (LASA), and oxidative stress were measured in mammary tissue and liver mitochondrial fraction. The results showed ductal hyperplasia and an increase in TSA, LASA, lipid peroxidation, and nitrite levels with a decrease in the antioxidants on DMBA treatment. Pretreatment with celecoxib and fish oil in DMBA-treated animals led to normal histology, increase in DNA fragmentation, and decrease in TSA and LASA levels with reduced oxidative stress, and the effect was more pronounced than animals pretreated with either celecoxib/fish oil alone suggesting a synergistic effect of the two regimens. To conclude, a combination of celecoxib and fish oil is a better strategy for cancer chemoprevention than celecoxib/fish oil alone.
Kansal
Shevali
S
Department of Biochemistry, Panjab University, Chandigarh 160014, India.
Negi
Anjana K
AK
Kaur
Ravneet
R
Sarotra
Pooja
P
Sharma
Gayatri
G
Aggarwal
Ritu
R
Agnihotri
Navneet
N
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D000068579:Celecoxib; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use*; D005969:Glutamate Dehydrogenase / Q000378:metabolism; D015227:Lipid Peroxidation; D008055:Lipids; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000517:prevention & control*; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D019158:N-Acetylneuraminic Acid / Q000378:metabolism; D018384:Oxidative Stress; D011720:Pyrazoles / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000627:therapeutic use*
D002273:Carcinogens; D052246:Cyclooxygenase 2 Inhibitors; D005395:Fish Oils; D008055:Lipids; D011720:Pyrazoles; D013449:Sulfonamides; C054080:lipid-associated sialic acid; D015127:9,10-Dimethyl-1,2-benzanthracene; D051546:Cyclooxygenase 2; D005969:Glutamate Dehydrogenase; D019158:N-Acetylneuraminic Acid; D000068579:Celecoxib